We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+27.83%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$130M
AUM Growth
+$3.84M
Cap. Flow
-$22.7M
Cap. Flow %
-17.42%
Top 10 Hldgs %
57.06%
Holding
85
New
22
Increased
8
Reduced
24
Closed
13

Top Buys

Rank Stock Value
1
AGTC
Applied Genetic Technologies Corporation
AGTC
+$2.44M
2
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$1.79M
3
OTIC
Otonomy, Inc.
OTIC
+$1.71M
4
ASND icon
Ascendis Pharma A/S
ASND
+$1.7M
5
ZGNX
Zogenix, Inc.
ZGNX
+$1.21M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$7.59M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$4.31M
3
OCRX
Ocera Therapeutics, Inc.
OCRX
+$4.04M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$3.36M
5
NVDQ
Novadaq Technologies Inc.
NVDQ
+$2.4M

Sector Composition

Rank Sector Weight
1 Healthcare 65.5%
2 Miscellaneous 34.26%
3 Financials 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCYC
1
DELISTED
PHARMACYCLICS INC
PCYC
$18.3M 14.08%
71,628
-39,300
-35% -$7.59M
ATRC icon
2
AtriCure
ATRC
$2.47B
$13.1M 10.03%
637,431
-23,900
-4% -$463K
ASPX
3
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$12.1M 9.28%
120,500
-15,385
-11% -$1.02M
NXTM
4
DELISTED
NxStage Medical Inc.
NXTM
$6.34M 4.87%
366,554
-17,600
-5% -$311K
WINT
5
DELISTED
Windtree Therapeutics Inc
WINT
$5.75M 4.41%
344,991
-62,062
-15% -$1.22M
AERI
6
DELISTED
Aerie Pharmaceuticals
AERI
$5.02M 3.86%
160,242
+27,800
+21% +$806K
RIGL icon
7
Rigel Pharmaceuticals
RIGL
$868M
$3.96M 3.04%
110,974
+36,067
+48% +$989K
PODD icon
8
Insulet
PODD
$10.1B
$3.54M 2.71%
106,018
-3,400
-3% -$115K
DSCI
9
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$3.17M 2.43%
373,918
-10,876
-3% -$92.6K
STXS icon
10
Stereotaxis
STXS
$145M
$2.81M 2.16%
1,716,078
-2,641
-0.2% -$4.21K
MTEM
11
DELISTED
Molecular Templates, Inc.
MTEM
$2.54M 1.95%
3,791
+573
+18% +$377K
ACHN
12
DELISTED
Achillion Pharmaceuticals
ACHN
$2.38M 1.83%
241,600
+44,100
+22% +$551K
PLX icon
13
Protalix BioTherapeutics
PLX
$205M
$2.19M 1.68%
123,079
-15,310
-11% -$300K
AGTC
14
DELISTED
Applied Genetic Technologies Corporation
AGTC
$2.19M 1.68%
+109,323
New +$2.44M
MASI
15
DELISTED
Masimo
MASI
$2.18M 1.67%
66,000
-1,500
-2% -$43.1K
BEAT
16
DELISTED
BioTelemetry, Inc.
BEAT
$2.08M 1.6%
235,645
– –
OTIC
17
DELISTED
Otonomy, Inc.
OTIC
$1.77M 1.36%
+50,000
New +$1.71M
CLVS
18
DELISTED
Clovis Oncology, Inc.
CLVS
$1.74M 1.33%
23,400
-500
-2% -$35.3K
NVDQ
19
DELISTED
Novadaq Technologies Inc.
NVDQ
$1.65M 1.27%
101,841
-161,700
-61% -$2.4M
ZSPH
20
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$1.65M 1.26%
+39,100
New +$1.79M
ASND icon
21
Ascendis Pharma A/S
ASND
$16.3B
$1.62M 1.25%
+93,541
New +$1.7M
EVFM
22
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$1.53M 1.18%
2,076
+4
+0.2% +$2.56K
BCRX icon
23
BioCryst Pharmaceuticals
BCRX
$2.51B
$1.5M 1.16%
166,656
– –
SPNC
24
DELISTED
Spectranetics Corp
SPNC
$1.38M 1.06%
39,812
-2,350
-6% -$79.9K
GYRE icon
25
Gyre Therapeutics
GYRE
$699M
$1.38M 1.06%
591
– –
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, DAFNA Capital Management held 85 positions worth $130M, up 3% from $126M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

DAFNA Capital Management withdrew a net $22.7M in Q1 2015, closing 13 positions and reducing 24 holdings. Its most notable exit was Ocera Therapeutics, Inc., an estimated $4.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 74% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, DAFNA Capital Management opened a new position in Applied Genetic Technologies Corporation worth $2.19M.

  • DAFNA Capital Management's largest Q1 2015 buy was Applied Genetic Technologies Corporation: 109,323 shares worth $2.19M.
  • DAFNA Capital Management added most to Rigel Pharmaceuticals in Q1 2015, an estimated $989K increase.
  • DAFNA Capital Management's biggest Q1 2015 reduction was PHARMACYCLICS INC, cutting an estimated $7.59M.
  • DAFNA Capital Management fully exited Ocera Therapeutics, Inc. in Q1 2015, selling an estimated $4.04M.
  • DAFNA Capital Management's ten largest holdings make up 57% of its $130M portfolio in Q1 2015.
  • DAFNA Capital Management opened 22 new positions and closed 13 in Q1 2015.
  • DAFNA Capital Management's portfolio value rose 3% quarter-over-quarter to $130M.

Based on DAFNA Capital Management's 13F filing for Q1 2015, filed 15 May 2015.